United States

Alimera Sciences Inc (ALIM.O)

ALIM.O on Consolidated Issue listed on NASDAQ Global Market

21 Oct 2016
Change (% chg)

$-0.03 (-2.21%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ALIM.O


Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The... (more)


Beta: 3.41
Market Cap(Mil.): $86.14
Shares Outstanding(Mil.): 64.77
Dividend: --
Yield (%): --


  ALIM.O Industry Sector
P/E (TTM): -- 36.28 36.15
EPS (TTM): -0.67 -- --
ROI: -70.42 14.43 13.90
ROE: -- 15.21 14.83

BRIEF-Alimera Sciences strengthens financial position

* Under amendment, hercules has agreed to provide limited up to $10 million in additional financing upon achievement of certain revenue milestones

Oct 20 2016

BRIEF-Great point reports 5.12 pct passive stake in Alimera Sciences - SEC filing

* Great Point Partners Llc reports 5.12 percent passive stake in alimera sciences inc as of Aug. 11 - sec filing Source text for Eikon: Further company coverage:

Aug 22 2016

BRIEF-Alimera Sciences prices public offering of common stock

* Says public offering of 18.0 million common shares priced at $1.40per share Source text for Eikon: Further company coverage:

Aug 11 2016

BRIEF-Alimera Sciences proposes public offering of common stock

* All shares in offering are to be sold by Alimera, with net proceeds to be used to fund continued commercialization of Iluvien Source text for Eikon: Further company coverage:

Aug 10 2016

BRIEF-Alimera Sciences Q2 GAAP loss per share $0.15

* Alimera sciences announces second quarter 2016 financial results and provides business update

Aug 03 2016

BRIEF-Alimera Sciences sees Q2 revenue of $9.3 mln - $9.5 mln

* Says modified liquidity and revenue covenants in its existing loan agreement with Hercules Capital Inc

Jul 26 2016

BRIEF-Alimera Sciences reports Q1 GAAP loss per share $0.25

* Alimera sciences announces first quarter 2016 financial results

May 04 2016


Earnings vs. Estimates